Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
